Effect of *Helicobacter pylori* status on intragastric pH during treatment with omeprazole

E F Verdú, D Armstrong, R Fraser, F Viani, J-P Idström, C Cederberg, A L Blum

Abstract

To test the hypothesis that *Helicobacter pylori* infection is associated with a decreased intragastric acidity during omeprazole therapy, ambulatory 24 hour dual point gastric pH recordings were performed in 18 *H pylori* positive and 14 *H pylori* negative subjects. There was a four to six week washout period between the two pH recordings made in each subject after one week courses of placebo or omeprazole, 20 mg daily. During placebo, median 24 hour pH values were not different in the corpus (*H pylori* positive = 1.5, negative = 1.4; p = 0.9) or antrum (*H pylori* positive = 1.3, negative = 1.2; p = 0.1). However, during omeprazole treatment, median 24 hour pH values were higher in *H pylori* positive subjects, both in the corpus (*H pylori* positive = 5.5, negative = 4.0; p = 0.001) and antrum (*H pylori* positive = 5.5, negative = 3.5; p = 0.0004). During placebo treatment, the only difference between the two groups was a higher later nocturnal pH in the antrum in the *H pylori* positive group. During omeprazole treatment, gastric pH was higher both in the corpus and in the antrum in the *H pylori* positive group for all periods, except for mealtime in the corpus. These data indicate that omeprazole produces a greater decrease in gastric acidity in subjects with *H pylori* infection than in those who are *H pylori* negative. It is not, however, known whether there is a causal relationship between *H pylori* infection and increased omeprazole efficacy.

(Gut 1995; 36: 539–543)

Keywords: Acid inhibition, *Helicobacter pylori*, omeprazole, intragastric pH-metry.

Omeprazole has been shown to have both direct1 and indirect2,3 effects on *Helicobacter pylori*, but it is not known whether infection with the organism may itself influence gastric acidity during omeprazole therapy. It has been reported that during treatment with omeprazole, the intragastric pH is higher in patients with duodenal ulceration than in healthy controls.4,5 It is unclear whether this reduction in gastric acidity is observable in all subjects with *H pylori* infection, or whether it is confined to a subset of patients who develop peptic ulceration. If the increased susceptibility to omeprazole is related solely to *H pylori* infection then *H pylori* negative subjects and *H pylori* positive subjects without ulceration should show different degrees of acid suppression in response to an equal dose of omeprazole.

To test the hypothesis that *H pylori* infection is associated with decreased intragastric acidity during treatment with omeprazole, we have conducted gastric pH-metry in *H pylori* positive individuals and compared the pH data with those obtained previously in 14 *H pylori* negative individuals.

Methods

SUBJECTS

Fourteen *H pylori* negative healthy subjects (seven men and seven women, age range: 22–46 years) and 18 *H pylori* positive subjects (11 men and seven women, age range: 22–45 years) were studied. Students and employees of a university hospital who had volunteered for an *H pylori* screening programme were also invited to participate in the present study. *H pylori* status was determined using the 13C urea breath test performed before enrolment and confirmed serologically by a specific ELISA technique (Roche), in the *H pylori* positive group.

None of the subjects had a history of gastrointestinal disease or other illnesses. At the time of enrolment, all were asymptomatic and were taking no medication except the oral contraceptive pill or paracetamol. Subjects were excluded if they had a history of alcohol or drug abuse. Smokers were not excluded from the study, but they were asked not to smoke during pH-metry.

All subjects gave written, informed consent, and the study was conducted according to the Declaration of Helsinki. The protocol was approved by the local ethical committee.

PROTOCOL

Treatment plan

Subjects received a one week course of omeprazole (20 mg once daily) and a one week course of placebo. The *H pylori* negative subjects received placebo and omeprazole treatment sequentially, following a single blind design. The *H pylori* positive subjects were treated in a randomised, cross over, double blind fashion. Washout periods lasted four to six weeks between treatments.

24 hour pH-metry

At the end of each one week treatment period, 24 hour intragastric pH-metry was performed using a standard protocol. Subjects arrived at
the laboratory at 08:00 hours after an overnight fast. The pH measuring assembly was passed through an anaesthetised nostril and positioned fluoroscopically, so that the proximal pH electrode was located in the corpus, 5 cm from the cardia, and the second electrode was located in the antrum, 7-5 cm distally. Recordings started at 08:30 and standard meals, prepared in the hospital, were provided for all subjects. After the supervised ingestion of the study medication at 08:45, subjects returned home with instructions to eat breakfast at 09:15, lunch at 13:00, and supper at 19:00. At the start of the recording, subjects were provided with two litres of water to be consumed during the study, but other beverages were not allowed. Subjects retired to bed at 22:00 and arose at 06:00 to return to the laboratory by 08:15. The position of the assembly was checked before removal at 08:30. Subjects were instructed to use the event marker on the data logger to mark the start and end of each meal, the times at which they retired to bed and got up, and the occurrence of any other important event.

Equipment

Intragastric pH measurements were performed using two combined glass pH electrodes (BK2801C, Radiometer, Copenhagen, Denmark). The electrodes were covered by a silicon rubber tube (OD/ID 3-0 mm/2-5 mm) with one electrode at the tip and the other situated at 7-5 cm proximally. The electrodes were connected to a 512 kbyte memory data logger (LZ-105, Kaufhold, Berlin, Germany), in which electrode potentials were stored without prior processing. The pH electrodes were calibrated before and after each recording, using standard buffer solutions of pH 1-09 and 7-38 at room temperature (S1368 and S1356, Radiometer, Copenhagen, Denmark). At the end of each recording, data were transferred to a computer (Atari-Mega-ST4, Atari Sunnyvale, CA, USA) running under the OS-9 operating system (Microware, Des Moines, IA, USA), and were transformed to pH values after correction for buffer temperature and 24 hour pH electrode drift. Data were transferred to a computer disk for later analysis and storage.

Results

Fourteen H pylori negative subjects completed the study and no adverse events attributable to omeprazole were detected. Seventeen H pylori positive subjects completed the study. Data from one H pylori positive subject were excluded when the subject was found to be achlorhydric (median 24 hour pH of 6.2 during administration of placebo). A second subject was withdrawn during omeprazole treatment and replaced, because of the development of high transaminase activities which returned to normal after stopping treatment.

Figure 1: $^{13}$C urea breath test results in the H pylori positive group at enrolment, after omeprazole treatment, after placebo and after washout periods of four to six weeks. The broken line shows normal cut off value for excess $\delta^{13}$CO$_2$ per mil, horizontal bars show median values. Four transiently negative breath tests were observed during omeprazole treatment and one was observed during placebo administration. All subjects had a positive result after washout periods.

$^{13}$C urea breath test

In all subjects, breath tests were performed before enrolment. In subjects found to be H pylori positive, additional breath tests were conducted before and after each treatment week. Two breath samples were obtained before and 30 minutes after administration of 100 mg of $^{13}$C urea mixed in 100 ml orange juice. The ratio $\delta^{13}$CO$_2$/\$^{12}$CO$_2$ was measured by mass spectrometry; the ratio in the 30 minute sample was subtracted from that in the baseline breath sample and compared with a reference value. Results were expressed as excess delta $\delta^{13}$CO$_2$ per thousand (\$^{13}$CO$_2$ per mil), and a value of >5 was considered as a positive result.

DATA ANALYSIS AND STATISTICAL EVALUATION

As in previous studies we predefined the following time intervals; entire recording (0830-0830), mealtime periods (0915-1115, 1300-1500, 1900-2100), night-time (2200-0600), and the remaining combined non-meal daytime period. The overall night-time period was divided into early (22:00-02:00) and late (02:00-06:00) night-time; individual median pH values for each period of interest were obtained for statistical analysis. Summary 24 hour pH curves for each individual were obtained by calculating consecutive 1 minute median pH values resulting in 1440 data points; group curves are presented as means for H pylori positive and H pylori negative groups.

The Mann-Whitney U test was used to compare median pH values between groups and the Wilcoxon rank test for paired data was used to compare pH values within each group. Multiple comparisons between breath test values at enrolment, after treatments, and after washout periods were performed using the Friedman test, followed by Wilcoxon-Wilcox.

The following tests were done: 

- Wilcoxon signed rank test
- Friedman rank test
- Mann-Whitney U test
- Wilcoxon-Wilcox test

In all calculations, the level of significance was set at p<0.05.
Helicobacter pylori and omeprazole efficacy

13C UREA BREATH TEST AND SEROLOGY

The median \( \delta ^{13} \text{CO}_2 \) per mil did not change after the placebo treatment period compared with the values obtained at enrolment; one subject had a negative breath test after placebo but it became positive after the washout period. The median \( \delta ^{13} \text{CO}_2 \) per mil was lower after omeprazole treatment period than at enrolment (\( p<0.01 \)) or after placebo (\( p<0.01 \)), but the effect was transient and after the washout period the breath tests were again positive in the four subjects whose breath tests had become negative after omeprazole (Fig 1).

All subjects who had a positive breath test also had a positive serology. Transiently negative breath tests were also associated with positive serology, although serological titres in these four cases were lower than those obtained during enrolment (data not shown).

### Table 1: Median pH values (95% CI) in the corpus for the entire 24 hour recording and for other time periods during the placebo and omeprazole treatment phases in Helicobacter pylori positive (HP+ve) and negative (HP−ve) subjects

<table>
<thead>
<tr>
<th>Time</th>
<th>Placebo</th>
<th>Omeprazole</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HP+ve</td>
<td>HP−ve</td>
</tr>
<tr>
<td>24 Hours</td>
<td>1.5 (1.3-1.7)</td>
<td>1.4 (1.2-2.0)</td>
</tr>
<tr>
<td>Mealtime</td>
<td>2.3 (2.1-3.0)</td>
<td>2.0 (1.6-2.9)</td>
</tr>
<tr>
<td>Daytime</td>
<td>1.3 (1.2-1.7)</td>
<td>1.4 (1.2-2.1)</td>
</tr>
<tr>
<td>Night-time</td>
<td>1.1 (0.9-1.8)</td>
<td>1.1 (1.0-1.8)</td>
</tr>
<tr>
<td>Early night-time</td>
<td>1.0 (0.9-1.2)</td>
<td>0.9 (0.7-1.3)</td>
</tr>
<tr>
<td>Late night-time</td>
<td>1.4 (1.2-3.1)</td>
<td>1.2 (1.0-1.3)</td>
</tr>
</tbody>
</table>

### Figure 2: Placebo mean pH curves for the corpus (upper), and antrum (lower) 24 hour recordings in H pylori positive subjects (heavy line) and H pylori negative subjects (thin line). Similar median 24 hour gastric pH values were observed in both groups, in the corpus (\( p=0.9 \)) and in the antrum (\( p=0.1 \)).

### Discussion

During omeprazole treatment, the median 24 hour pH values in the \( H \) pylori positive subjects were appreciably higher than in the \( H \) pylori negative subjects. The difference was evident during the entire recording, except for mealtime periods, but was most noticeable during the nocturnal part of the recording. In contrast, during placebo treatment, the median 24 hour pH values did not differ between the two groups and the 24 hour pH profiles were similar.

Previous studies have suggested that omeprazole might produce a greater fall in gastric acidity in duodenal ulcer patients than in healthy subjects, but it was not possible to say whether this was a result of the presumed \( H \) pylori infection or whether it was associated rather with an ulcer diathesis in these patients. The results of the present study suggest that it may be the \( H \) pylori infection, and not the ulcer diathesis, which is associated with the greater susceptibility to omeprazole.

It seems likely that the \( H \) pylori related accentuation of omeprazole induced gastric hypacidity is prolonged since this interaction would be consistent with the efficacy of omeprazole noted in duodenal ulcer patients. However, it is not clear whether this interaction will persist after eradication of \( H \) pylori, and, if it does persist, how long it will be evident. At present, the mechanisms underlying the interaction between \( H \) pylori and omeprazole are unknown and it is, therefore, difficult to predict the possible consequences. It is possible that the presence of \( H \) pylori and its subsequent suppression or eradication in patients with reflux oesophagitis (a disease unrelated to \( H \) pylori) may change the therapeutic efficacy of a given dose of omeprazole. If the \( H \) pylori related effect is dependent on the presence and concentration of \( H \) pylori in the gastric mucosa, it is also possible that the suppression of \( H \) pylori in patients with peptic
ulcer disease who are pretreated with omeprazole may alter the efficacy of eradication regimens which require the concomitant administration of an antisecretory agent.

The mechanisms responsible for the enhanced effect of omeprazole on intragastric pH in the _H. pylori_ positive subjects are unclear. It may be that _H. pylori_ has only an indirect effect on the efficacy of omeprazole, related to the development of an immune cell infiltrate and gastritis. Mononuclear cells produce factors which liberate gastrin and stimulate acid secretion by histamine release from enterochromaffin-like cells. It is, therefore, possible that gastritis is responsible for the decreased antral somatostatin and increased plasma gastrin seen in _H. pylori_ infection. The resulting parietal cell stimulation would decrease the intracanalicular pH, leading either to increased transformation of omeprazole into the active sulphenamide form, or to increased availability of proton pumps susceptible to the activated omeprazole.

It has been reported that _H. pylori_ density decreases in the antrum and increases in the corpus after four weeks of omeprazole therapy. Theoretically, this could increase the exposure of parietal cells to a variety of substances released by _H. pylori_ which can inhibit acid secretion in vitro. However, the subjects in the present study received omeprazole at a lower dose for only one week and it is unknown whether this would, in fact, be adequate to produce the reported redistribution of _H. pylori_ within the stomach and a consequent improvement of the gastritis sufficient to affect gastric acidity. The fact that the 13C urea breath test became transiently negative in only a minority of subjects (Fig 1), suggests that the decreased acidity was not due to an effect of omeprazole on _H. pylori_ density. Confirmation of this supposition would, however, require gastric pH studies earlier and later during the course of omeprazole therapy with endoscopic biopsies from the antrum and corpus to monitor changes in _H. pylori_ density and mucosal inflammation.

The daytime intragastric pH profiles found during placebo administration in both groups are similar and consistent with the pH curves recorded in healthy subjects in previous studies. The nocturnal pH increases in _H. pylori_ positive subjects appear an exaggeration of the pattern observed in _H. pylori_ negative subjects. We have previously shown that although nocturnal alkalisation may be partly caused by duodenogastric reflux, other possibilities, such as mucosal wedging of the antral electrode, must also be considered. The more noticeable peaks in pH found in the _H. pylori_ positive group could be explained by an effect of the organism on gastric motility, leading to more rapid gastric emptying of acid or to increased reflux. However, no clear relationship has been established between _H. pylori_ infection and altered gastrointestinal motility. Acid hyposecretion, as a result of either mucosal atrophy or direct inhibition of acid production induced by _H. pylori_ infection, is another possible explanation for the higher nocturnal pH found in _H. pylori_ positive subjects during omeprazole treatment. It is unlikely that any of the _H. pylori_ positive subjects in this study had gastric mucosal atrophy, since they were, in general, young, and the pH curves during placebo administration showed no evidence of hypoacidity. On the other hand, acid secretory inhibitors produced by _H. pylori_ have been investigated only in vitro and their clinical relevance is not known.

Ammonia and carbamate produced by _H. pylori_ and the consequent neutralisation of secreted gastric acid may also be responsible for the increased gastric pH observed during omeprazole administration in _H. pylori_ positive subjects. Studies investigating this possible mechanism will probably require prolonged monitoring of intragastric ammonia.

Although indirect, the current study suggests an important interaction between

Table II Median pH values (95% CI) in the antrum for the entire 24 hour recording and for other time periods during the placebo and omeprazole treatment phases in _Helicobacter pylori_ positive (HP+ ve) and negative (HP− ve) subjects

<table>
<thead>
<tr>
<th>Time</th>
<th>Placebo HP+ ve</th>
<th>Placebo HP− ve</th>
<th>Omeprazole HP+ ve</th>
<th>Omeprazole HP− ve</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 Hours</td>
<td>1±3 (1.1–2.3)</td>
<td>1±2 (1.1–1.4)</td>
<td>5±5 (4.5–5.7)</td>
<td>3±5 (2.0–4.2)</td>
</tr>
<tr>
<td>Mealtime</td>
<td>1±5 (1.3–2.2)</td>
<td>1±4 (1.1–1.5)</td>
<td>5±5 (4.6–5.5)</td>
<td>4±4 (2.0–4.8)</td>
</tr>
<tr>
<td>Daytime</td>
<td>1±2 (0.9–1.9)</td>
<td>1±2 (1.0–1.4)</td>
<td>5±6 (4.4–5.7)</td>
<td>2±8 (1.6–4.0)</td>
</tr>
<tr>
<td>Night-time</td>
<td>1±5 (1.4–3.3)</td>
<td>1±2 (1.0–1.4)</td>
<td>5±8 (3.9–5.9)</td>
<td>2±5 (1.4–3.6)</td>
</tr>
<tr>
<td>Early night-time</td>
<td>1±1 (0.9–1.1)</td>
<td>1±0 (0.9–1.1)</td>
<td>2±8 (1.6–4.3)</td>
<td>p=0.003</td>
</tr>
<tr>
<td>Late night-time</td>
<td>4±1 (2.7–4.8)</td>
<td>1±1 (1.4–1.6)</td>
<td>6±8 (6.0–7.0)</td>
<td>p=0.003</td>
</tr>
</tbody>
</table>

Figure 3: Mean pH curves for the corpus (upper) and antrum (lower) 24 hour recordings in _H. pylori_ positive subjects (heavy line) and _H. pylori_ negative subjects (thin line) during omeprazole therapy. Gastric acidity was decreased to a much greater extent by omeprazole in _H. pylori_ positive subjects (corpus: p=0.001; antrum: p=0.004) than in _H. pylori_ negative subjects.

Verdú, Armstrong, Frazer, Viani, Idström, Cederberg, Blum
Helicobacter pylori and omeprazole efficacy

opemrrole and H pylori status. Direct evidence will require the investigation of H pylori positive subjects tested before and after eradication. As the effects of H pylori infection on gastric feedback mechanisms, such as gastrin, may be long lasting,23 37 such studies should allow sufficient time after H pylori eradication for healing of associated gastritis, which may itself modify gastric acidity.

In conclusion, H pylori infected subjects have a higher intragastric pH during treatment with omeprazole than H pylori negative subjects, although there is no difference between the two groups with regard to gastric acidity in the absence of omeprazole. Further studies are required to determine whether the increased susceptibility to omeprazole is a consequence, directly or indirectly, of H pylori infection or whether the increased omeprazole efficacy and H pylori infection are co-phenomena associated with another underlying abnormality.

Supported by Swiss National Fund 32-36349.92.

Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole.

E F Verdú, D Armstrong, R Fraser, F Viani, J P Idström, C Cederberg and A L Blum

Gut 1995 36: 539-543
doi: 10.1136/gut.36.4.539

Updated information and services can be found at:
http://gut.bmj.com/content/36/4/539

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Campylobacter, Salmonella, Shigella, Escherichia coli (242)
Helicobacter pylori (218)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/